Business Context and Reporting Period
This Form 8-K filing by Karyopharm Therapeutics Inc. reports a corporate governance event dated August 31, 2018. The filing details the election of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and associated compensation arrangements rather than financial performance.
Material Changes
- Board Composition: The Board increased the number of directors from seven to eight.
- Director Election: F. Carsten Thiel, Ph.D., was elected as a Class II director, with a term expiring at the 2021 annual meeting of stockholders.
- Class II Directors: The number of Class II directors increased from one to two.
Compensation and Governance Details
In connection with his election, Dr. Thiel received the following compensation and arrangements:
- Cash Retainer: An annual cash retainer of $38,000, prorated from the effective date to the 2019 annual meeting.
- Stock Option Grant: An option to purchase 34,000 shares of common stock at an exercise price of $21.05 per share (the closing price on the grant date).
- Vesting Schedule: One-third of the shares vest on the first anniversary of the grant date; the remaining shares vest monthly (1/36th per month) over the subsequent two years, subject to continued service.
- Indemnification: The Company entered into a standard indemnification agreement covering legal expenses and liabilities arising from his service as a director.
Investor Verification Checklist
- Verify the total number of outstanding shares and the potential dilution impact of the 34,000 new options granted.
- Confirm the current stock price relative to the $21.05 exercise price to assess the intrinsic value of the grant.
- Review the Company's proxy statement for the 2019 annual meeting to confirm the prorated retainer calculation and total director compensation.
- Check for any subsequent filings regarding Dr. Thiel's committee assignments or additional equity grants.